ClinicalTrials.gg
CompletedNCT01026974Updated Oct 1, 2014Results posted

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine

A Phase 2 interventional study of rMenB and rMenB+OMV NZ in Meningococcal Disease, sponsored by Novartis Vaccines. Completed at 1 site in United Kingdom. Open to participants aged 40 Months to 62 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-01.

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
40 Months to 62 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.

Enrollment
16th of 21
120 · median 508
Started
2010
with 1 other
Phase 2
7 of 21
1 open now
Registered
7th of 21
by date
Lead sponsor
10 of 21
Novartis Vaccines

Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 16th largest by enrollment, is one of 2 that started in 2010, is one of 7 in phase 2, and was the 7th registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 4CMenB vaccine

4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 40 Months to 62 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing 4CMenB vaccine in Meningococcal Infections, or all of them as a file.
02

Study summary

The proposed study V72P9E1 is an Extension Study of V72P9. The objectives of this extension study will be to explore antibody persistence in children at approximately 40 months of age and to evaluate the safety, tolerability and immunogenicity of a booster dose of rMenB±OMV NZ administered to subjects at approximately 40 months of age. Antibody persistence will be subsequently measured at 18-20 months after these booster doses when the subjects are 60 months of age. Two groups of naïve subjects, aged approximately 40 and 60 months, will be recruited in the study to serve as a baseline comparator for assessing antibody persistence at these ages. These subjects will receive a two-dose catch-up regimen with rMenB+OMV NZ. Subjects who are enrolled at 40 months of age are offered DTaP/IPV and MMR vaccinations , if they have not already received these vaccines prior to enrollment.

03

Conditions studied

  • Meningococcal Disease

Keywords

  • Children
  • Pre-school
  • Meningococcal disease
  • Prevention
  • Vaccination
04

Who can participate

Ages eligible
40 Months to 62 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy 40 to 44-months-old children, who participated and completed the study V72P9 (follow-on subjects)
  • Healthy 40 to 44-months or 60 to 62-months-old children (naïve subjects)

Exclusion criteria

Exclusion Criteria:

  • Previous ascertained or suspected disease caused by N meningitidis
  • History of severe allergic reaction after previous vaccinations or to any vaccine component
  • Any serious chronic or progressive disease
  • Known or suspected impairment/ alteration of the immune system
  • Receipt of, or intent to immunize with another vaccine, within 30 days prior and after vaccination with the vaccines (within 14 days for licensed flu vaccines)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    4rMenB

    Subjects received three primary doses of rMenB vaccine (at the age of 6-8 months; 2 months after and at 12 months) in parent study (NCT00433914) and one booster dose of rMenB vaccine at 40 months of age in the present study.

    Biological: rMenB

  • Experimental
    4rMenB+OMV NZ

    Subjects received three primary doses of rMenB+OMV NZ vaccine (at the age of 6-8months; 2 months after and at 12 months) in parent study (NCT00433914) and one booster dose of rMenB+OMV NZ vaccine at 40 months of age in the present study.

    Biological: rMenB+OMV NZ

  • Experimental
    Naive_4042

    Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.

    Biological: rMenB+OMV NZ

  • Experimental
    Naive_6062

    Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study.

    Biological: rMenB+OMV NZ

Interventions

06

What researchers measure

Primary outcomes

  1. Persistence of Serum Bactericidal Antibody Titers in Children (at 40 Months of Age), Twenty-eight Months After Completing Primary Vaccination.

    The geometric mean antibody titers (GMTs) against Neisseria meningitidis serogroup B in children (at 40 months of age); twenty-eight months after completion of primary vaccination with either rMenB or rMenB+OMV NZ vaccines, are compared with the GMTs in vaccine-naïve children.

    Time frame: 28 months after primary vaccination; Baseline for Naïve

  2. Percentage of Subjects With Persisting Serum Bactericidal Antibodies Titers ≥4, Twenty-eight Months After Completing Primary Vaccination.

    The percentages of subjects with persisting serum bactericidal antibodies (hSBA) titers ≥4, against N meningitidis serogroup B at 40 months of age; twenty-eight months after completion of primary vaccination with either rMenB or rMenB+OMV NZ as compared to the vaccine-naïve children are reported. The serum bactericidal antibodies directed against serogroup B meningococci, are measured by human complement Serum Bactericidal Assay (hSBA).

    Time frame: 28 months after primary vaccination; Baseline for Naïve

  3. Number of Subjects Reporting Solicited Local and Systemic Adverse Events After a Booster Dose of rMenB or rMenB+OMV NZ Vaccine at Forty Months of Age.

    The safety and tolerability of a single booster dose of rMenB or rMenB+OMV NZ vaccine in 40 month old children who had previously received three primary doses of the same vaccine as infants in parent study was assessed in terms of number of subjects with solicited local and systemic reactions following vaccination and compared to tolerability in vaccine-naive children who received 1st catch-up dose of rMenB+OMV NZ at 40 months of age.

    Time frame: Day 1 to Day 7 [after booster vaccination /post dose 1 for naive]

Secondary outcomes

  1. Serum Bactericidal Antibody Titers in Children After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age

    The serum bactericidal antibody response one month after a booster dose of rMenB or rMenB+OMV NZ vaccine was given to children at 40 months of age is compared with the antibody titers following one catch-up dose rMenB+OMV NZ vaccine given at 40 months to vaccine-naive subjects and reported as GMTs.

    Time frame: 1 month post booster /1 month post dose 1 for Naïve

  2. Percentage of Subjects With Serum Bactericidal Antibody Titers ≥4 After Receiving a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine at 40 Months of Age

    The percentages of subjects with hSBA titers ≥4 against N meningitidis serogroup B one month after receiving a single booster dose of rMenB or rMenB+OMV NZ vaccine at 40 months of age, is compared with hSBA response following one catch-up dose of rMenB+OMV NZ vaccine given at 40 months in vaccine-naive subjects.

    Time frame: 1 month post-booster/ 1 month post-dose 1 for Naïve

  3. Percentage of Subjects With a 4-fold Increase in Antibody Titers After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age

    The percentages of subjects with four-fold increase in hSBA titers over baseline against N meningitidis serogroup B, one month after receiving a single booster dose of rMenB or rMenB+OMV NZ vaccine at 40 months of age, and compared with 4-fold increase in hSBA titers following one catch-up dose of rMenB+OMV NZ vaccine given at 40 months to vaccine-naive subjects. Baseline was defined as either the time that the (first) booster dose was given (i.e. at 40 months of age) or the time of the first vaccination (i.e. at 40 months of age for Naive_4042 group.

    Time frame: 1 month post booster / 1 month post dose 1 for Naïve

  4. Persistence of Serum Bactericidal Antibody Titers in Children (at 60 Months of Age), Twenty Months After Receiving a Booster Dose of rMenB or rMenB+OMV NZ Vaccine

    The persisting serum bactericidal antibody titers in children (at 60 months of age), twenty months after receiving a booster dose of either rMenB or rMenB+OMV NZ vaccine (at 40 months of age) is compared with the antibody titers in vaccine -naïve subjects of the same age and reported as GMTs.

    Time frame: 20 months post booster/ Baseline for Naïve

  5. Percentage of Subjects With Persisting Serum Bactericidal Antibody Titers ≥4, Twenty Months After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine

    The percentage of subjects (60 months of age) with persisting hSBA titers ≥4, twenty months after receiving a booster dose of either rMenB or rMenB+OMV NZ vaccine (at 40 months of age) are compared with hSBA response in vaccine-naïve subjects of the same age.

    Time frame: 20 months post booster/ Baseline for Naïve

  6. Percentage of Subjects With Serum Bactericidal Antibody Titers ≥4 Following Two Doses of rMenB+OMV NZ Vaccine Given One Month Apart, Either at 40 or 60 Months of Age

    The percentage of subjects with hSBA titers ≥4 after two catch-up doses of rMenB+OMV NZ vaccine when given either at- 40 \& 42 months or 60 \& 62 months of age is reported.

    Time frame: 1 month post -vaccine dose two

  7. Serum Bactericidal Antibody Titers in Children Following Two Doses of rMenB+OMV NZ Vaccine Given One Month Apart, Either at 40 or 60 Months of Age.

    The serum bactericidal antibody response in children after two catch-up doses of rMenB+OMV NZ vaccine when given either at- 40 \& 42 months or 60 \& 62 months of age are reported as GMTs.

    Time frame: 1 month post vaccine dose two

  8. Percentage of Subjects With a 4-fold Increase in Antibody Titers After Two Catch up Doses of rMenB+OMV NZ Vaccine Given One Month Apart Either at 40 or 60 Months of Age

    The percentages of subjects with four-fold increase in hSBA titers over baseline against N meningitidis serogroup B one month after receiving a two catch-up doses of rMenB+OMV NZ vaccine either at 40 \& 42 months or 60 \& 62 months of age.

    Time frame: 1 month post vaccine dose 2

  9. Persistence of Serum Bactericidal Antibody Titers in Children (at 60 Months), Eighteen Months After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine.

    The serum bactericidal antibody response in children at 60 months of age who had received two catch-up doses of rMenB+OMV NZ vaccine at- 40 \& 42 months age is reported as GMTs.

    Time frame: 18 months post vaccine dose 2

  10. Percentage of Subjects With Serum Bactericidal Antibody Titers ≥4, Eighteen Months After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine.

    Persisting hSBA titers ≥4 in children at 60 months of age, who had received two catch-up doses of rMenB+OMV NZ vaccine at 40 \& 42 months age is reported.

    Time frame: 18 months post vaccine dose two

  11. Geometric Mean Antibody Concentrations in Children (at 40 Months of Age), Twenty Eight Months After Completing Primary Vaccination.

    The persisting geometric mean antibody concentrations (GMCs) against vaccine antigen 287-953 in children (at 40 months of age), twenty-eight months after completion of primary vaccination with either rMenB or rMen+OMV NZ vaccines, are compared with the GMCs in vaccine-naïve children. GMCs against vaccine antigen 287-953 were measured using enzyme linked immunosorbent assay (ELISA).

    Time frame: 28 months after primary vaccination/ Baseline for Naïve

  12. Geometric Mean Antibody Concentrations in Children, After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age.

    The GMCs against vaccine antigen 287-953, in children one month after receiving a single booster dose of either rMenB or rMen+OMV NZ vaccine , is compared with GMCs following one catch-up dose of rMenB+ OMV NZ in children at 40 months.

    Time frame: 1 month post booster /1 month post dose 1 for Naïve

  13. Geometric Mean Antibody Concentrations in Children (at 60 Months of Age), Twenty Months After Receiving a Booster Dose of rMenB or rMenB+OMV NZ Vaccine

    The persisting GMCs against vaccine antigen 287-953 in children (at 60 months of age), twenty months after receiving a booster dose of either rMenB or rMenB+OMV NZ vaccine (at 40 months), are compared with GMCs in vaccine-naïve children of same age.

    Time frame: 20 months post booster/ Baseline for Naïve

  14. Geometric Mean Antibody Concentrations in Children After Two Doses of rMenB+OMV NZ Vaccine Given One Month Apart, Either at 40 Months or 60 Months of Age.

    The GMCs against vaccine antigen 287-953 in children after two catch-up doses of rMenB+OMV NZ vaccine when given either at 40- \& 42- months or 60- \& 62- months of age are reported.

    Time frame: 1 month post vaccine dose two

  15. Geometric Mean Antibody Concentrations in Children (at 60 Months), Eighteen Months After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine.

    Persistence of GMCs against vaccine antigen 287-953 in children (60 months of age), eighteen months after two catch-up doses of rMenB+OMV NZ vaccine given at 40 months of age.

    Time frame: 18 months post vaccine dose 2

  16. Percentage of Subjects With Four Fold Increase in Geometric Mean Antibody Concentrations , After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age

    The percentage of subjects with four fold increase in GMCs over baseline against vaccine antigen 287-953 one month after receiving a single booster dose of either rMenB or rMen+OMV NZ vaccine, is compared with responses following one catch-up dose of rMenB+OMV NZ in children at 40 months.

    Time frame: 1 month post booster / 1 month post dose 1

  17. Percentage of Subjects With 4-fold Increase in Geometric Mean Antibody Concentrations, After Two Catch-up Doses of rMenB+OMV NZ Vaccine Given One Month Apart Either at 40 or 60 Months of Age

    The percentages of subjects with four-fold increase in GMCs over baseline against vaccine antigen 287-953, one month after receiving a two catch-up doses of rMenB+OMV NZ vaccine either at 40 \& 42 months or 60 \& 62 months of age.

    Time frame: 1 month post dose 2

  18. Number of Children Reporting Solicited Local and Systemic Adverse Events After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine One Month Apart, Either at 40 or 60 Months of Age

    The safety and tolerability of a two doses of rMenB+OMV NZ vaccine in children when given either at 40 \& 42 months or 60 \& 62 months of age is assessed in terms of number of subjects with solicited local and systemic reactions following vaccination.

    Time frame: Day 1-7 after each vaccination

07

Results

Posted Mar 11, 2014

Participant flow

Subjects were recruited from a single center.

Participant flow — Overall Study
Milestone4rMenB4rMenB+OMV NZNaive_4042Naive_6062
Started16144149
Completed15122946
Not completed12123
Withdrew: Withdrawal by subject0172
Withdrew: Lost to follow-up1140
Withdrew: Adverse event0001
Withdrew: Inappropriate enrollment0010

Outcome measures

PrimaryPersistence of Serum Bactericidal Antibody Titers in Children (at 40 Months of Age), Twenty-eight Months After Completing Primary Vaccination.

The geometric mean antibody titers (GMTs) against Neisseria meningitidis serogroup B in children (at 40 months of age); twenty-eight months after completion of primary vaccination with either rMenB or rMenB+OMV NZ vaccines, are compared with the GMTs in vaccine-naïve children.

Time frame:
28 months after primary vaccination; Baseline for Naïve
Reported as:
Geometric mean · Titers
Persistence of Serum Bactericidal Antibody Titers in Children (at 40 Months of Age), Twenty-eight Months After Completing Primary Vaccination.
Titers4rMenB4rMenB+OMV NZNaive_4042
44/76-SL strain (N = 14,14,39)1.26 (0.9 to 1.76)2.55 (1.15 to 5.66)1.08 (0.97 to 1.2)
5/99 strain (N = 14,14,40)41 (18 to 95)29 (18 to 47)1 (1 to 1)
NZ98/254 strain (N = 15,14,39)1 (1 to 1)1.74 (0.91 to 3.33)1 (1 to 1)
M10713 strain ( N = 14,14,40)3.6 (1.32 to 9.84)7.11 (3.61 to 14)4.82 (2.9 to 8)
SecondarySerum Bactericidal Antibody Titers in Children After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age

The serum bactericidal antibody response one month after a booster dose of rMenB or rMenB+OMV NZ vaccine was given to children at 40 months of age is compared with the antibody titers following one catch-up dose rMenB+OMV NZ vaccine given at 40 months to vaccine-naive subjects and reported as GMTs.

Time frame:
1 month post booster /1 month post dose 1 for Naïve
Reported as:
Geometric mean · Titers
Serum Bactericidal Antibody Titers in Children After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age
Titers4rMenB4rMenB+OMV NZNaive_4042
44/76-SL strain (N = 13,14,39)100 (50 to 200)114 (59 to 222)8.89 (5.83 to 14)
5/99 strain (N=14, 14, 39)1007 (445 to 2277)926 (432 to 1988)27 (16 to 44)
NZ98/254 strain (N=14, 14, 39)2.15 (0.88 to 5.23)32 (14 to 71)1.91 (1.35 to 2.71)
M10713 strain (N = 13,14,39)10 (3.43 to 30)23 (13 to 41)6.04 (3.73 to 9.79)
PrimaryPercentage of Subjects With Persisting Serum Bactericidal Antibodies Titers ≥4, Twenty-eight Months After Completing Primary Vaccination.

The percentages of subjects with persisting serum bactericidal antibodies (hSBA) titers ≥4, against N meningitidis serogroup B at 40 months of age; twenty-eight months after completion of primary vaccination with either rMenB or rMenB+OMV NZ as compared to the vaccine-naïve children are reported. The serum bactericidal antibodies directed against serogroup B meningococci, are measured by human complement Serum Bactericidal Assay (hSBA).

Time frame:
28 months after primary vaccination; Baseline for Naïve
Reported as:
Number · percentages of subjects
Percentage of Subjects With Persisting Serum Bactericidal Antibodies Titers ≥4, Twenty-eight Months After Completing Primary Vaccination.
percentages of subjects4rMenB4rMenB+OMV NZNaive_4042
44/76-SL strain (N = 14,14,39)14 (2 to 43)36 (13 to 65)3 (0.065 to 13)
5/99 strain (N = 14,14,40)93 (66 to 100)100 (77 to 100)0 (0 to 9)
NZ98/254 strain (N = 15,14,39)0 (0 to 22)14 (2 to 43)0 (0 to 9)
M10713 strain (N = 14,14,40)29 (8 to 58)79 (49 to 95)53 (36 to 68)
PrimaryNumber of Subjects Reporting Solicited Local and Systemic Adverse Events After a Booster Dose of rMenB or rMenB+OMV NZ Vaccine at Forty Months of Age.

The safety and tolerability of a single booster dose of rMenB or rMenB+OMV NZ vaccine in 40 month old children who had previously received three primary doses of the same vaccine as infants in parent study was assessed in terms of number of subjects with solicited local and systemic reactions following vaccination and compared to tolerability in vaccine-naive children who received 1st catch-up dose of rMenB+OMV NZ at 40 months of age.

Time frame:
Day 1 to Day 7 [after booster vaccination /post dose 1 for naive]
Reported as:
Number · participants
Number of Subjects Reporting Solicited Local and Systemic Adverse Events After a Booster Dose of rMenB or rMenB+OMV NZ Vaccine at Forty Months of Age.
participants4rMenB4rMenB+OMV NZNaive_4042
Local141438
Injection-site pain101234
Injection-site erythema131436
Injection-site swelling9610
Injection-site induration11517
Systemic121130
Change in eating habits5513
Sleepiness6620
Vomiting021
Diarrhea212
Irritability81124
Headache214
Arthralgia239
Rash212
Fever (≥38°C)416
Other61021
Temperature (≥40°C)001
Antipyretic preventive medication used4919
Antipyretic treatment medication used315
Medically attended fever000
SecondaryPercentage of Subjects With Serum Bactericidal Antibody Titers ≥4 After Receiving a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine at 40 Months of Age

The percentages of subjects with hSBA titers ≥4 against N meningitidis serogroup B one month after receiving a single booster dose of rMenB or rMenB+OMV NZ vaccine at 40 months of age, is compared with hSBA response following one catch-up dose of rMenB+OMV NZ vaccine given at 40 months in vaccine-naive subjects.

Time frame:
1 month post-booster/ 1 month post-dose 1 for Naïve
Reported as:
Number · percentages of subjects
Percentage of Subjects With Serum Bactericidal Antibody Titers ≥4 After Receiving a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine at 40 Months of Age
percentages of subjects4rMenB4rMenB+OMV NZNaive_4042
44/76-SL strain (N = 13, 14, 39)100 (75 to 100)100 (77 to 100)72 (55 to 85)
5/99 strain (N=14, 14, 39)100 (77 to 100)100 (77 to 100)87 (73 to 96)
NZ98/254 strain (N=14, 14, 39)21 (5 to 51)93 (66 to 100)23 (11 to 39)
M10713 strain (N = 13, 14, 39)69 (39 to 91)93 (66 to 100)62 (45 to 77)
SecondaryPercentage of Subjects With a 4-fold Increase in Antibody Titers After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age

The percentages of subjects with four-fold increase in hSBA titers over baseline against N meningitidis serogroup B, one month after receiving a single booster dose of rMenB or rMenB+OMV NZ vaccine at 40 months of age, and compared with 4-fold increase in hSBA titers following one catch-up dose of rMenB+OMV NZ vaccine given at 40 months to vaccine-naive subjects. Baseline was defined as either the time that the (first) booster dose was given (i.e. at 40 months of age) or the time of the first vaccination (i.e. at 40 months of age for Naive_4042 group.

Time frame:
1 month post booster / 1 month post dose 1 for Naïve
Reported as:
Number · percentages of subjects
Percentage of Subjects With a 4-fold Increase in Antibody Titers After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age
percentages of subjects4rMenB4rMenB+OMV NZNaive_4042
44/76-SL strain (N = 11,14,37)100 (72 to 100)93 (66 to 100)54 (37 to 71)
5/99 strain (N = 12,14,38)100 (74 to 100)100 (77 to 100)76 (60 to 89)
NZ98/254 strain (N = 13,14,37)23 (5 to 54)71 (42 to 92)11 (3 to 25)
M10713 strain (N = 11,14,38)18 (2 to 52)36 (13 to 65)5 (1 to 18)
SecondaryPersistence of Serum Bactericidal Antibody Titers in Children (at 60 Months of Age), Twenty Months After Receiving a Booster Dose of rMenB or rMenB+OMV NZ Vaccine

The persisting serum bactericidal antibody titers in children (at 60 months of age), twenty months after receiving a booster dose of either rMenB or rMenB+OMV NZ vaccine (at 40 months of age) is compared with the antibody titers in vaccine -naïve subjects of the same age and reported as GMTs.

Time frame:
20 months post booster/ Baseline for Naïve
Reported as:
Geometric mean · Titers
Persistence of Serum Bactericidal Antibody Titers in Children (at 60 Months of Age), Twenty Months After Receiving a Booster Dose of rMenB or rMenB+OMV NZ Vaccine
Titers4rMenB4rMenB+OMV NZNaive_6062
44/76-SL strain (N = 9,12,46)9.37 (2.47 to 36)4.69 (1.98 to 11)1.09 (0.96 to 1.25)
5/99 strain (N = 9,11,46)334 (186 to 599)119 (56 to 252)1.17 (0.96 to 1.42)
NZ98/254 strain (N = 10,12,46)1 (1 to 1)1.63 (0.86 to 3.08)1 (1 to 1)
M10713 strain (N = 8,11,45)4.96 (1.03 to 24)5.51 (2.19 to 14)8.09 (5.13 to 13)
SecondaryPercentage of Subjects With Persisting Serum Bactericidal Antibody Titers ≥4, Twenty Months After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine

The percentage of subjects (60 months of age) with persisting hSBA titers ≥4, twenty months after receiving a booster dose of either rMenB or rMenB+OMV NZ vaccine (at 40 months of age) are compared with hSBA response in vaccine-naïve subjects of the same age.

Time frame:
20 months post booster/ Baseline for Naïve
Reported as:
Number · percentages of subjects
Percentage of Subjects With Persisting Serum Bactericidal Antibody Titers ≥4, Twenty Months After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine
percentages of subjects4rMenB4rMenB+OMV NZNaive_6062
44/76-SL strain (N = 9,12,46)67 (30 to 93)67 (35 to 90)4 (1 to 15)
5/99 strain (N = 9,11,46)100 (66 to 100)100 (72 to 100)4 (1 to 15)
NZ98/254 strain 10, 12, 46)0 (0 to 31)17 (2 to 48)0 (0 to 8)
M10713 strain (N = 8,11,45)50 (16 to 84)45 (17 to 77)67 (51 to 80)
SecondaryPercentage of Subjects With Serum Bactericidal Antibody Titers ≥4 Following Two Doses of rMenB+OMV NZ Vaccine Given One Month Apart, Either at 40 or 60 Months of Age

The percentage of subjects with hSBA titers ≥4 after two catch-up doses of rMenB+OMV NZ vaccine when given either at- 40 \& 42 months or 60 \& 62 months of age is reported.

Time frame:
1 month post -vaccine dose two
Reported as:
Number · percentages
Percentage of Subjects With Serum Bactericidal Antibody Titers ≥4 Following Two Doses of rMenB+OMV NZ Vaccine Given One Month Apart, Either at 40 or 60 Months of Age
percentagesNaive_4042Naive_6062
44/76-SL strain (N = 30,34)100 (88 to 100)100 (90 to 100)
5/99 strain (N = 31,34)100 (89 to 100)100 (90 to 100)
NZ98/254 strain (N=31, 35)90 (74 to 98)89 (73 to 97)
M10713 strain (N = 29,33)72 (53 to 87)97 (84 to 100)
SecondarySerum Bactericidal Antibody Titers in Children Following Two Doses of rMenB+OMV NZ Vaccine Given One Month Apart, Either at 40 or 60 Months of Age.

The serum bactericidal antibody response in children after two catch-up doses of rMenB+OMV NZ vaccine when given either at- 40 \& 42 months or 60 \& 62 months of age are reported as GMTs.

Time frame:
1 month post vaccine dose two
Reported as:
Geometric mean · Titers
Serum Bactericidal Antibody Titers in Children Following Two Doses of rMenB+OMV NZ Vaccine Given One Month Apart, Either at 40 or 60 Months of Age.
TitersNaive_4042Naive_6062
44/76-SL strain (N = 30,34)74 (57 to 94)83 (67 to 103)
5/99 strain (N = 31,34)247 (188 to 323)331 (254 to 432)
NZ98/254 strain (N = 30,35)16 (11 to 23)14 (9.81 to 21)
M10713 strain (N = 29,33)8.91 (5.19 to 15)44 (33 to 57)
SecondaryPercentage of Subjects With a 4-fold Increase in Antibody Titers After Two Catch up Doses of rMenB+OMV NZ Vaccine Given One Month Apart Either at 40 or 60 Months of Age

The percentages of subjects with four-fold increase in hSBA titers over baseline against N meningitidis serogroup B one month after receiving a two catch-up doses of rMenB+OMV NZ vaccine either at 40 \& 42 months or 60 \& 62 months of age.

Time frame:
1 month post vaccine dose 2
Reported as:
Number · percentages of subjects
Percentage of Subjects With a 4-fold Increase in Antibody Titers After Two Catch up Doses of rMenB+OMV NZ Vaccine Given One Month Apart Either at 40 or 60 Months of Age
percentages of subjectsNaive_4042Naive_6062
44/76-SL strain (N = 29,34)100 (88 to 100)100 (90 to 100)
5/99 strain (N = 31,34)100 (89 to 100)100 (90 to 100)
NZ 98/254 strain (N = 30,35)73 (54 to 88)69 (51 to 83)
M10713 strain (N = 29,32)24 (10 to 44)53 (35 to 71)
SecondaryPersistence of Serum Bactericidal Antibody Titers in Children (at 60 Months), Eighteen Months After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine.

The serum bactericidal antibody response in children at 60 months of age who had received two catch-up doses of rMenB+OMV NZ vaccine at- 40 \& 42 months age is reported as GMTs.

Time frame:
18 months post vaccine dose 2
Reported as:
Geometric mean · Titers
Persistence of Serum Bactericidal Antibody Titers in Children (at 60 Months), Eighteen Months After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine.
TitersNaive_4042
44/76-SL strain2.73 (1.54 to 4.84)
5/99 strain24 (16 to 35)
NZ98/254 strain1 (1 to 1)
M10713 strain (N = 23)14 (6.78 to 27)
SecondaryPercentage of Subjects With Serum Bactericidal Antibody Titers ≥4, Eighteen Months After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine.

Persisting hSBA titers ≥4 in children at 60 months of age, who had received two catch-up doses of rMenB+OMV NZ vaccine at 40 \& 42 months age is reported.

Time frame:
18 months post vaccine dose two
Reported as:
Number · percentages of subjects
Percentage of Subjects With Serum Bactericidal Antibody Titers ≥4, Eighteen Months After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine.
percentages of subjectsNaive_4042
44/76-SL strain38 (19 to 59)
5/99 strain100 (86 to 100)
NZ98/254 strain0 (0 to 14)
M10713 strain (N = 23)83 (61 to 95)
SecondaryGeometric Mean Antibody Concentrations in Children (at 40 Months of Age), Twenty Eight Months After Completing Primary Vaccination.

The persisting geometric mean antibody concentrations (GMCs) against vaccine antigen 287-953 in children (at 40 months of age), twenty-eight months after completion of primary vaccination with either rMenB or rMen+OMV NZ vaccines, are compared with the GMCs in vaccine-naïve children. GMCs against vaccine antigen 287-953 were measured using enzyme linked immunosorbent assay (ELISA).

Time frame:
28 months after primary vaccination/ Baseline for Naïve
Reported as:
Geometric mean · concentrations (AU/mL)
Geometric Mean Antibody Concentrations in Children (at 40 Months of Age), Twenty Eight Months After Completing Primary Vaccination.
concentrations (AU/mL)4rMenB4rMenB+OMV NZNaive_4042
Geometric Mean Antibody Concentrations in Children (at 40 Months of Age), Twenty Eight Months After Completing Primary Vaccination.86 (43 to 173)103 (61 to 174)27 (22 to 35)
SecondaryGeometric Mean Antibody Concentrations in Children, After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age.

The GMCs against vaccine antigen 287-953, in children one month after receiving a single booster dose of either rMenB or rMen+OMV NZ vaccine , is compared with GMCs following one catch-up dose of rMenB+ OMV NZ in children at 40 months.

Time frame:
1 month post booster /1 month post dose 1 for Naïve
Reported as:
Geometric mean · concentrations (AU/mL)
Geometric Mean Antibody Concentrations in Children, After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age.
concentrations (AU/mL)4rMenB4rMenB+OMV NZNaive_4042
Geometric Mean Antibody Concentrations in Children, After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age.5187 (2924 to 9204)3662 (2065 to 6491)83 (52 to 133)
SecondaryGeometric Mean Antibody Concentrations in Children (at 60 Months of Age), Twenty Months After Receiving a Booster Dose of rMenB or rMenB+OMV NZ Vaccine

The persisting GMCs against vaccine antigen 287-953 in children (at 60 months of age), twenty months after receiving a booster dose of either rMenB or rMenB+OMV NZ vaccine (at 40 months), are compared with GMCs in vaccine-naïve children of same age.

Time frame:
20 months post booster/ Baseline for Naïve
Reported as:
Geometric mean · concentrations (AU/mL)
Geometric Mean Antibody Concentrations in Children (at 60 Months of Age), Twenty Months After Receiving a Booster Dose of rMenB or rMenB+OMV NZ Vaccine
concentrations (AU/mL)4rMenB4rMenB+OMV NZNaive_6062
Geometric Mean Antibody Concentrations in Children (at 60 Months of Age), Twenty Months After Receiving a Booster Dose of rMenB or rMenB+OMV NZ Vaccine772 (395 to 1512)358 (201 to 640)25 (19 to 33)
SecondaryGeometric Mean Antibody Concentrations in Children After Two Doses of rMenB+OMV NZ Vaccine Given One Month Apart, Either at 40 Months or 60 Months of Age.

The GMCs against vaccine antigen 287-953 in children after two catch-up doses of rMenB+OMV NZ vaccine when given either at 40- \& 42- months or 60- \& 62- months of age are reported.

Time frame:
1 month post vaccine dose two
Reported as:
Geometric mean · concentrations (AU/mL)
Geometric Mean Antibody Concentrations in Children After Two Doses of rMenB+OMV NZ Vaccine Given One Month Apart, Either at 40 Months or 60 Months of Age.
concentrations (AU/mL)Naive_4042Naive_6062
Geometric Mean Antibody Concentrations in Children After Two Doses of rMenB+OMV NZ Vaccine Given One Month Apart, Either at 40 Months or 60 Months of Age.612 (329 to 1139)2164 (1663 to 2817)
SecondaryGeometric Mean Antibody Concentrations in Children (at 60 Months), Eighteen Months After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine.

Persistence of GMCs against vaccine antigen 287-953 in children (60 months of age), eighteen months after two catch-up doses of rMenB+OMV NZ vaccine given at 40 months of age.

Time frame:
18 months post vaccine dose 2
Reported as:
Geometric mean · concentrations (AU/mL)
Geometric Mean Antibody Concentrations in Children (at 60 Months), Eighteen Months After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine.
concentrations (AU/mL)Naive_4042
Geometric Mean Antibody Concentrations in Children (at 60 Months), Eighteen Months After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine.87 (63 to 120)
SecondaryPercentage of Subjects With Four Fold Increase in Geometric Mean Antibody Concentrations , After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age

The percentage of subjects with four fold increase in GMCs over baseline against vaccine antigen 287-953 one month after receiving a single booster dose of either rMenB or rMen+OMV NZ vaccine, is compared with responses following one catch-up dose of rMenB+OMV NZ in children at 40 months.

Time frame:
1 month post booster / 1 month post dose 1
Reported as:
Number · percentages of subjects
Percentage of Subjects With Four Fold Increase in Geometric Mean Antibody Concentrations , After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age
percentages of subjects4rMenB4rMenB+OMV NZNaive_4042
Percentage of Subjects With Four Fold Increase in Geometric Mean Antibody Concentrations , After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age100 (77 to 100)100 (77 to 100)21 (10 to 37)
SecondaryPercentage of Subjects With 4-fold Increase in Geometric Mean Antibody Concentrations, After Two Catch-up Doses of rMenB+OMV NZ Vaccine Given One Month Apart Either at 40 or 60 Months of Age

The percentages of subjects with four-fold increase in GMCs over baseline against vaccine antigen 287-953, one month after receiving a two catch-up doses of rMenB+OMV NZ vaccine either at 40 \& 42 months or 60 \& 62 months of age.

Time frame:
1 month post dose 2
Reported as:
Geometric mean · percentages of subjects
Percentage of Subjects With 4-fold Increase in Geometric Mean Antibody Concentrations, After Two Catch-up Doses of rMenB+OMV NZ Vaccine Given One Month Apart Either at 40 or 60 Months of Age
percentages of subjectsNaive_4042Naive_6062
Percentage of Subjects With 4-fold Increase in Geometric Mean Antibody Concentrations, After Two Catch-up Doses of rMenB+OMV NZ Vaccine Given One Month Apart Either at 40 or 60 Months of Age77 (59 to 90)97 (85 to 100)
SecondaryNumber of Children Reporting Solicited Local and Systemic Adverse Events After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine One Month Apart, Either at 40 or 60 Months of Age

The safety and tolerability of a two doses of rMenB+OMV NZ vaccine in children when given either at 40 \& 42 months or 60 \& 62 months of age is assessed in terms of number of subjects with solicited local and systemic reactions following vaccination.

Time frame:
Day 1-7 after each vaccination
Reported as:
Number · participants
Number of Children Reporting Solicited Local and Systemic Adverse Events After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine One Month Apart, Either at 40 or 60 Months of Age
participantsNaive_4042Naive_6062
Local3948
Injection-site pain3846
Injection-site erythema3846
Injection-site swelling1932
Injection-site induration2628
Systemic3948
Change in eating habits2015
Sleepiness2626
Vomiting47
Diarrhea44
Irritability2929
Headache812
Arthralgia1324
Rash35
Fever (≥38°C)1010
Other2126
Antipyretic Preventive medication used2429
Antipyretic Treatment medication used812
Temperature(≥40°C)10
Medically attended fever10

Adverse events

Collected over Solicited AEs were collected from Day 1 to Day 7 after each vaccination, SAEs and other unsolicited AEs were collected throughout the study [approximately 20 months for Groups rMenB; rMenB+OMV NZ and Naive_4042 and Days 1-91 for Naive_6062 group].. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
4rMenB—1/16 (6.3%)15/16 (93.8%)
4rMenB+OMV NZ—1/14 (7.1%)14/14 (100%)
Naive_4042—4/41 (9.8%)41/41 (100%)
Naive_6062—1/48 (2.1%)48/48 (100%)
Most frequent serious events
Most frequent serious events
Event4rMenB4rMenB+OMV NZNaive_4042Naive_6062
Upper respiratory tract infectionInfections and infestations0/161/140/410/48
LymphadenitisBlood and lymphatic system disorders1/160/140/410/48
VomitingGastrointestinal disorders0/160/141/410/48
Croup infectiousInfections and infestations0/160/141/410/48
GastroenteritisInfections and infestations0/160/141/410/48
EncephalitisNervous system disorders0/160/141/410/48
Febrile convulsionNervous system disorders0/160/141/410/48
AsthmaRespiratory, thoracic and mediastinal disorders0/160/140/411/48
Most frequent other events
Showing 10 of 36
Most frequent other events
Event4rMenB4rMenB+OMV NZNaive_4042Naive_6062
Injection site erythemaGeneral disorders13/1614/1440/4146/48
Injection site painGeneral disorders10/1612/1438/4146/48
IrritabilityGeneral disorders8/1611/1429/4129/48
Injection site indurationGeneral disorders11/165/1426/4128/48
Injection site swellingGeneral disorders9/166/1420/4132/48
SomnolenceNervous system disorders6/166/1426/4126/48
ArthralgiaMusculoskeletal and connective tissue disorders2/163/1413/4124/48
Eating disorderPsychiatric disorders5/165/1420/4115/48
HeadacheNervous system disorders2/161/148/4113/48
PyrexiaGeneral disorders4/161/1411/4110/48

Baseline characteristics

Age, Continuous
Age, Continuous(months)4rMenB4rMenB+OMV NZNaive_4042Naive_6062Total
Mean42.8 ± 1.143.1 ± 0.941.7 ± 1.761.3 ± 0.750.0 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)4rMenB4rMenB+OMV NZNaive_4042Naive_6062Total
Female811222162
Male83192858
08

Study locations

1 site
  • Oxford Vaccine Group, Center for Clinical Vaccinology and Tropical Medicine, Churchill Hospital
    Oxford, OX3 7LJ, United Kingdom
09

References and documents

Publications

  • McQuaid F, Snape MD, John TM, Kelly S, Robinson H, Houlden J, Voysey M, Toneatto D, Kitte C, Dull PM, Pollard AJ. Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age. Pediatr Infect Dis J. 2014 Jul;33(7):760-6. doi: 10.1097/INF.0000000000000327. PubMed 24722351 ↗
  • Snape MD, Philip J, John TM, Robinson H, Kelly S, Gossger N, Yu LM, Kittel C, Toneatto D, Dull PM, Pollard AJ. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. Pediatr Infect Dis J. 2013 Oct;32(10):1116-21. doi: 10.1097/INF.0b013e31829cfff2. PubMed 23958808 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Sep 2010 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2009
First posted
Dec 7, 2009
Start
Feb 2010
Primary completionActual
Sep 2010
CompletionActual
May 2012
Results first posted
Mar 11, 2014
Last update
Oct 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01026974
Lead sponsor
Novartis Vaccines
Responsible party
Sponsor
First posted
Dec 7, 2009
Start date
Feb 2010
Primary completion
Sep 2010
Completion
May 2012
Results posted
Mar 11, 2014
Last update
Oct 1, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4CMenB vaccine

Start the discussion